Compare Medtronic PLC (MDT) vs D Wave Quantum Inc (QBTS) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

D-Wave Quantum (QBTS) trades at $16.73 with no change on the day, showing bearish technical signals despite a 100% analyst buy rating and $39.86 consensus price target. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains deeply negative profitability metrics with a -2,957.23% net income margin. Recent news highlights CEO share sales and sector volatility, while the stock's 29% July decline reflects investor concerns about execution risks in the emerging quantum computing space.

QBTS offers substantial upside potential based on analyst targets but carries high risk due to significant losses, negative cash flow from operations, and speculative technology timeline. The dual-platform quantum strategy provides competitive differentiation, but investors face volatility from pre-commercialization phase challenges and dependence on future funding rounds to sustain operations.